$TROV Speculation and rumors grab our attention.

The month of MAY has been quite interesting for NASDAQ:TROV having released earnings that beat but revenue that missed, it followed this up by securing a capital raise with Lincoln Park Capital Funds, which adds additional working capital to move forward with it clinical development programs.
Speculation and rumors are quite active in the social platforms regarding a upcoming positive move in the stock, like any Medical company these moves can happen when least expected, so have alerts or orders set as the price is now sitting on strong support.
Analyst Average price target $15.50
Analyst Average Recommendation BUY

COMPANY PROFILE
Trovagene, Inc. is a clinical-stage, precision medicine oncology therapeutics company. Its focuses on developing PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor.